Table 2.
Follow-up treatment patterns and utilization for matched continuers and switchers
| CC (n=605) | SC (n=92) | ||||
|---|---|---|---|---|---|
|
| |||||
| n/mean | %/SD | n/mean | %/SD | P-value | |
| Average duration of follow-up period (months) | 16.3 | 2.3 | 15.1 | 2.1 | <0.001 |
| Dosing characteristics | |||||
| No. of infusions in follow-up period | 4.8 | 2.4 | 2.9 | 2 | <0.001 |
| Weeks between administration | 9.7 | 3.7 | 10.7 | 5.7 | NS |
| Switching | |||||
| No. of switchers | 115 | 19.0% | 75 | 81.5% | <0.001 |
| Characteristics of switch (n=605 vs n=92) | |||||
| Golimumab | 24 | 4.0% | 2 | 2.2% | NS |
| Adalimumab | 35 | 5.8% | 5 | 5.4% | NS |
| Etanercept | 30 | 5.0% | 2 | 2.2% | NS |
| Abatacept | 4 | 0.7% | 0 | 0.0% | NS |
| Rituximab | 7 | 1.2% | 0 | 0.0% | NS |
| Anakinra | 1 | 0.2% | 0 | 0.0% | NS |
| Tocilizumab | 14 | 2.3% | 0 | 0.0% | NS |
| CT-P13 | 0 | ||||
| IFX | 66 | 71.7% | |||
| Discontinuation | |||||
| Time to discontinuation (days) | 275.7 | 123.6 | 132.2 | 104 | <0.001 |
| No. of DPI (mg) before discontinuation | 450 | 190 | 380 | 160 | <0.001 |
| No. of patients with discontinuation | 205 | 33.9% | 80 | 87.0% | <0.001 |
| Time to discontinuation for patients who truly discontinued (days) | 117.1 | 78.4 | 98.4 | 59.7 | 0.032 |
| Concomitant DMARD and RA-related treatment | |||||
| Hydroxychloroquine | 53 | 8.8% | 8 | 8.7% | NS |
| Sulfasalazine | 76 | 12.6% | 22 | 23.9% | 0.004 |
| Azathioprine | 78 | 12.9% | 5 | 5.4% | 0.040 |
| Cyclophosphamide | 2 | 0.3% | 1 | 1.1% | NS |
| Leflunomide | 54 | 8.9% | 13 | 14.1% | NS |
| Methotrexate/methotrexate sodium | 143 | 23.6% | 24 | 26.1% | NS |
| Tofacitinib | 7 | 1.2% | 0 | 0.0% | NS |
| NSAIDs | 512 | 84.6% | 81 | 88.0% | NS |
| Corticosteroids | 465 | 76.9% | 71 | 77.2% | NS |
| Duration of any IFX use (IFX or CT-P13) in baseline and follow-up periods | |||||
| Days (mean) | 704 | 375 | 637 | 373 | NS |
Abbreviations: CC, continuers cohort; DMARD, disease-modifying antirheumatic drug; DPI, dose per infusion; IFX, infliximab; NS, not significant; NSAID, nonsteroidal anti-inflammatory drug; RA, rheumatoid arthritis; SC, switchers cohort.